Dawei Tian

Medicine · Health Sciences

13h-index550citations86works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(39), Urinary and Genital Oncology Studies(17), Cancer Immunotherapy and Biomarkers(12), Esophageal Cancer Research and Treatment(9), Epigenetics and DNA Methylation(7)

Publications86 total

Implementation of family-centered care in Pediatric Gastroscopy
Pakistan Journal of Medical Sciences·2026Open Access
Survey of nutrition-related KAP levels in children and adolescents with early-onset severe obesity in Qinhuangdao city
Journal of the Pakistan Medical Association·2025Open Access
Sustained drug-releasing hydrogel coatings for ureteral stents to prevent iatrogenic injury-induced ureteral stricture
Materials Today Bio·2025Open Access
MIF Facilitates Resistance to Androgen Deprivation Therapy by Regulating AMPD2 Expression in Prostate Cancer Cells
The Prostate·2025
Pracinostat inhibits the nefarious biological behavior of pancreatic cancer by targeting the miR-381–3p/MDM2 axis to activate the p53 signaling pathway
Pathology - Research and Practice·2025· 1 cited
Integrin Tension Represents the Directed Differentiation of Mesenchymal Stem Cells via Mechanoadaptation
ACS Nano·2025· 1 cited
Clinical symptoms and epidemiological survey of early-onset severe obesity among children and adolescents
Pakistan Journal of Medical Sciences·2025Open Access
Supplementary Table S1 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025Open Access
Supplementary Table S4 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025Open Access
Data from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025Open Access
Supplementary Table S5 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025Open Access
Supplementary Figure S2 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025Open Access
Supplementary Table S2 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025Open Access
Supplementary Figure S1 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025Open Access
Supplementary Table S3 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025Open Access
Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
Clinical Cancer Research·2025· 5 citedOpen Access
Plaque enhancement of middle cerebral artery and pre-stroke diet are associated with prognosis of subacute ischemic stroke: A prospective high-resolution MR vessel wall imaging study
European Journal of Radiology·2024· 2 cited
Causal associations between gut microbiota and chronic prostatitis/chronic pelvic pain syndrome: a two-sample Mendelian randomization study
Egyptian Journal of Medical Human Genetics·2024· 2 citedOpen Access
Characterization and modulation of the unimolecular conformation of integrins with nanopore sensors
Chemical Engineering Journal·2024· 4 cited
Physiological Mechanisms of Reverse Pulmonary Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease
The Journal of Heart and Lung Transplantation·2024Open Access
page 1 of 5Next →

Frequent Co-authors

Changli Wu(23), Zhouliang Wu(20), Hailong Hu(15), La Da(9), Linguo Xie(8), Hailong Hu(8), Chong Shen(7), Jie Gao(7), Yunkai Qie(6), Zhonghua Shen(6), Wanqin Xie(6), Gangjian Zhao(6), Diansheng Zhou(6), Ruifa Han(5), Gang Tang(5), Chuan Qin(5), Yinlei Wang(5), Feiran Chen(5), Zhiyong Du(5), Shiwang Huang(5)